Groups Similar Look up By Text Browse About

Similar articles
Article Id Title Prob Score Similar Compare
220648 ARSTECHNICA 2021-11-19:
FDA authorizes Pfizer and Moderna COVID boosters for all adults
1.000 Find similar Compare side-by-side
220921 ARSTECHNICA 2021-11-19:
Adults nationwide eligible for boosters this weekend as CDC gives sign-off
0.948 0.678 Find similar Compare side-by-side
220739 THEVERGE 2021-11-19:
FDA clears Pfizer and Moderna COVID-19 boosters for all US adults
0.989 0.629 Find similar Compare side-by-side
220683 ARSTECHNICA 2021-11-17:
Boosters for all is critical, not a luxury, Fauci says as FDA decision nears
0.105 0.621 Find similar Compare side-by-side
220902 ARSTECHNICA 2021-11-22:
COVID surge underway with daily cases already above 93K ahead of holiday
0.425 Find similar Compare side-by-side
220488 ARSTECHNICA 2021-11-16:
Doctors are fighting back against fringe doctors pushing COVID misinformation
0.351 Find similar Compare side-by-side
220714 ZDNET 2021-11-19:
South Australia launches two digital tools for assessing travellers as part of opening border
0.277 Find similar Compare side-by-side
220861 VENTUREBEAT 2021-11-20:
The one thing we’re NOT doing to mitigate the spread of COVID-19
0.275 Find similar Compare side-by-side
220450 VENTUREBEAT 2021-11-17:
Report: Flawed data management leads to lost revenue for most companies
0.270 Find similar Compare side-by-side
220365 VENTUREBEAT 2021-11-16:
People Data Labs, which offers data as a service via APIs, raises $45M
0.269 Find similar Compare side-by-side
220432 VENTUREBEAT 2021-11-16:
Data management platform Bigeye unveils rapid dataset validation tool
0.251 Find similar Compare side-by-side
220646 VENTUREBEAT 2021-11-19:
Biopharma Industry Leaders Ian Read and Clive Meanwell Join Saama Board of Directors
0.251 Find similar Compare side-by-side
220627 ARSTECHNICA 2021-11-19:
Keeping science reproducible in a world of custom code and data
0.250 Find similar Compare side-by-side
220315 VENTUREBEAT 2021-11-17:
Groq accelerates COVID drug discovery at Argonne National Laboratory
0.249 Find similar Compare side-by-side
220747 VENTUREBEAT 2021-11-18:
Databricks integrates data tools with Partner Connect
0.242 Find similar Compare side-by-side
220778 TECHREPUBLIC 2021-11-17:
Data scientist shortage: Can your company use citizen data scientists?
0.242 Find similar Compare side-by-side
220559 VENTUREBEAT 2021-11-17:
Hightouch, which syncs data from warehouse to cloud apps, raises $40M
0.236 Find similar Compare side-by-side
220787 ZDNET 2021-11-18:
Grab finds sweet spot of data lake and data warehouse in its centralised data platform
0.228 Find similar Compare side-by-side
220769 ZDNET 2021-11-18:
MongoDB rolls out Atlas Data API for easier data access
0.226 Find similar Compare side-by-side
220604 ZDNET 2021-11-16:
Data Mesh: Should you try this at home?
0.226 Find similar Compare side-by-side
220772 TECHREPUBLIC 2021-11-18:
Office occupancy hits 25% in the US with NYC and Boston offices filling up the fastest
0.225 Find similar Compare side-by-side
220732 TECHREPUBLIC 2021-11-18:
Top 5 things to know about data intelligence
0.224 Find similar Compare side-by-side
220729 ARSTECHNICA 2021-11-19:
At least 25 poisoned, 1 dead from “Real Alkalized Water,” CDC report reveals
0.222 Find similar Compare side-by-side
220788 VENTUREBEAT 2021-11-17:
Fortanix reveals confidential AI for seamless app development
0.222 Find similar Compare side-by-side
220643 VENTUREBEAT 2021-11-19:
TruePlan brings data to companies’ headcount and hiring plans
0.217 Find similar Compare side-by-side


ID: 220648


Date: 2021-11-19

FDA authorizes Pfizer and Moderna COVID boosters for all adults

Booster doses could be available to all adults by this weekend. The Food and Drug Administration has authorized booster doses of both the Pfizer-BioNTech and Moderna COVID-19 vaccines for all people ages 18 and up, the companies announced separately this morning. The boosters are to be given at least six months after a person's second dose and, according to Moderna, can be used for mix-and-match boosting. That is, people who received two Pfizer-BioNTech vaccine doses earlier this year could get a Moderna booster and vice versa. Preliminary data released last month from a mix-and-match booster trial run by the National Institutes of Health found that Moderna boosters appeared to generate the highest antibody levels overall, including in people who had previously received two doses of the Pfizer-BioNTech vaccine. However, the trial used a full dose of the Moderna vaccine (100 micrograms) for a booster, whereas the FDA has authorized a half-dose shot (50 micrograms) for boosters. It's unclear if the half dose offers the same edge over boosting with a third Pfizer-BioNTech shot, which is given at the same dosage as the first two shots (30 micrograms). Regardless, the mix-and-match trial and clinical data from the two companies all found boosters to be safe and highly effective at restoring waning coronavirus antibodies to high levels. Todays FDA decision is supported by clinical data showing robust immune responses following a booster dose of our vaccine, exceeding what has been seen even after the completion of the highly effective two-dose primary schedule, BioNTech CEO and co-founder Ugur Sahin said in a statement. These data suggest a booster dose of our vaccine has the potential to maintain a high level of protection against tested variants, including delta. Following the FDA's authorization decision, the CDC's panel of independent vaccine experts will take up the matter to set official federal policy. They will meet today (Friday) at noon Eastern time for a relatively short three-hour meeting. The CDC panel—the Advisory Committee on Immunization Practices—will likely review the data and vote on whether to recommend booster doses for all adults. If they vote in favor, CDC director Dr. Rochelle Walensky will likely sign off on the recommendation quickly. If so, booster doses for all adults could become available nationwide over the weekend. A handful of states and cities have charged ahead of the FDA and CDC process. Booster doses are already open to all in several states, including Arkansas, California, Colorado, and New Mexico, as well as in New York City.